Upgrade to SI Premium - Free Trial

Amgen (AMGN) & Allergen (AGN) Report Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980

September 11, 2017 5:46 AM
Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced data from a Phase 3 study evaluating the efficacy and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles